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The current model for MLV genomic RNA (gRNA) packaging predicts that of the thousands of Gag
proteins in a budding virion, only a small number (r1%) may be necessary to recruit gRNA. Here, we
examined the threshold limits of functional Gag required to package gRNA using wild-type (WT) and
packaging deﬁcient mutant nucleocapsid (NC) phenotypically mixed virions. Although gRNA packaging
was severely diminished for the NC mutant, the residual encapsidated RNA dimer displayed motility on
gels, thermostability, and integrity that was indistinguishable from that of WT. In phenotypically mixed
virions, gRNA encapsidation recovered to within approximately two-fold of WT levels when the
amount of WT NC was 5–10% of the total. Our results demonstrate that NC’s roles in gRNA dimerization
and packaging are genetically separable. Additionally, MLV gRNA packaging does not require 100% WT
NC, but the amount of functional NC required is greater than the predicted minimum.
& 2012 Elsevier Inc. All rights reserved.Introduction
The retroviral Gag polyprotein is responsible for directing virus
assembly and genomic RNA (gRNA) packaging (reviewed in
D’Souza and Summers, 2005; Ganser-Pornillos et al., 2008; Lu
et al., 2011; Rein et al., 2011). The full-length Moloney murine
leukemia virus (MLV) Gag polyprotein, termed Pr65Gag, consists of
four structural domains: matrix (p15 MA), p12, capsid (p30 CA),
and nucleocapsid (p10 NC). The NC domain of Pr65Gag is respon-
sible for speciﬁc recruitment and packaging of MLV gRNA into
newly forming virions (Rein et al., 1994; Berkowitz et al., 1995;
Zhang and Barklis, 1995). MLV NC contains a single conserved
‘‘zinc knuckle’’ domain (C-X2-C-X4-H-X4-C; C¼Cys, H¼His,
X¼variable) (Henderson et al., 1981), which is required for NC–
gRNA interactions (Fig. 1A). Mutations within this domain disrupt
viral assembly, gRNA packaging, and infectivity (Gorelick et al.,
1988; Me´ric and Goff, 1989; Rein et al., 1994; Gonsky et al., 2001;
Muriaux et al., 2004).
The region of MLV gRNA bound by NC during packaging is
contained within the 50-untranslated region (UTR) and is known
asC (Psi) for ‘‘packaging signal’’ (Mann et al., 1983). Mutations or
deletions of MLV C result in gRNAs that are poorly packaged
(Mann et al., 1983; Fisher and Goff, 1998; Muriaux et al., 2001).ll rights reserved.
).
ancer Center, University ofMLV gRNAs are packaged as dimers that are coupled in a dimer
linkage structure (DLS). The DLS is deﬁned by sequences that
overlap with C, and studies have demonstrated that the two
regions, and therefore gRNA dimerization and packaging, are
intimately linked (reviewed in D’Souza and Summers, 2005).
The C/DLS region contains several conserved UCUG and related
Py–Py–Py–G (Py¼pyrimidine) high-afﬁnity NC binding sites
(D’Souza and Summers, 2004; Dey et al., 2005). Within the MLV
RNA monomer, these high-afﬁnity binding sites are sequestered
by base pairing interactions; however, upon dimerization these
sites are exposed and competent for NC binding (D’Souza and
Summers, 2004; Gherghe et al., 2010; Miyazaki et al., 2010a,b).
This molecular ‘‘switch’’ provides a mechanism for the preferen-
tial recruitment of MLV gRNA dimers into newly forming virions.
The MLV NC zinc knuckle contains a conserved tryptophan
(Trp 35) that plays a direct role in mediating NC-gRNA interac-
tions. Trp 35 coordinates the binding of NC to its conserved high-
afﬁnity UCUG binding sites on the gRNA dimer by deﬁning a
pocket into which the guanosine residue ﬁts and binds with high
afﬁnity (D’Souza and Summers, 2004; Dey et al., 2005). As shown
in Fig. 1B, the indole functional group of Trp 35 deﬁnes one side of
the guanosine binding pocket by aligning parallel with the planar
pyrimidine-imidazole ring system of guanosine 309 (which is in a
UCUG motif from MLV nucleotides 306–309). Similar guanosine
binding pockets deﬁned by conserved Trp and Phe residues are
also present on both of the HIV-1 NC zinc knuckles (Summers
et al., 1990; South et al., 1991; Morellet et al., 1992; Summers
et al., 1992; South and Summers, 1993). Disruption of the MLV
Fig. 1. Interactions between the MLV NC ‘‘zinc knuckle’’ domain and gRNA
high afﬁnity binding sites. (A) Schematic representation of the zinc knuckle of
MLV NC from amino acids 21 to 44. Trp 35 (W) is shown in bold. (B) The guanosine
binding site of the MLV zinc knuckle is deﬁned on one side by the side chain of Trp
35 and the other by the side chains of Ala 36, Ala 27, and Leu 21. The zinc atom is
shown coordinated by the cysteine (yellow) and histidine (blue) side chains of the
conserved ‘‘CCHC’’ zinc knuckle. Depicted here is guanosine (Gua) 309, which is in
a high afﬁnity UCUG binding site from MLV nucleotides 306–309.
Fig. 2. Virus release of W35G NC mutant MLV. (A) Diagram of MLV gag-pol-puro (GPP)
and pGPP(W35G) were derived. pGPP(WT) contains an SV40 driven puroR cassette in t
the NC of pGPP(WT). (B) RT activities of media from cells transfected with pGPP(WT)
endpoint dilution for the W35G mutant is shown relative to WT, which is set to 100%. Da
standard error of the means. (C) Western blots of virus lysates and (D) lysates of ET cel
and (D) lysates of 3T3 cells stably transduced with pGPP(WT) and pGPP(W35G). W3
pGPP(W35G).
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severe packaging defects (Gorelick et al., 1988; Me´ric and Goff, 1989).
The number of high-afﬁnity NC binding sites in both the MLV
RNA monomer and gRNA dimer has been revealed by in vitro
binding analysis. When in vitro transcribed RNAs consisting of
nucleotides 147–623 of the MLV 50-UTR are dimerized, approxi-
mately one dozen high-afﬁnity binding sites are available for
binding of recombinant NC. In contrast, when mutations in the
in vitro transcribed RNAs are introduced that inhibit dimerization,
only one or two high-afﬁnity binding sites are available on the
MLV monomer for recombinant NC binding (Miyazaki et al.,
2010a). This observation predicts that of the putative thousands
of copies of Pr65Gag in an MLV virion (by analogy to HIV; Carlson
et al., 2008), only about a dozen (or r1%) may need to engage in
high-afﬁnity NC-gRNA interactions to promote packaging.
To test the hypothesis that only a small number (r1%) of
gRNA binding competent Pr65Gag molecules may be required for
MLV gRNA packaging during virus assembly, a MLV mutant
containing a single tryptophan-to-glycine substitution at amino
acid position 35 within the zinc knuckle of NC was co-expressed
with WT NC to generate phenotypically mixed virions containingvectors. pNCA is the parental infectious MLV proviral clone from which pGPP(WT)
he place of env. pGPP(W35G) contains a single amino acid substitution (W35G) in
and pGPP(W35G). Quantiﬁcation by phosphorimager analysis of RT activity upon
ta represented are the mean of 6 independent experiments. Error bars indicate the
ls transfected with pGPP(WT) and pGPP(W35G). (E) Western blots of virus lysates
5G 1 and 2 represent two distinct clonal 3T3 cell lines stably transduced with
S.F. Johnson et al. / Virology 430 (2012) 100–109102both WT and W35G NCs. Single cycle replication properties and
the amounts and properties of gRNA packaging for mixed virions
containing limiting amounts of WT NC were examined directly.Results
W35G NC mutant virus production
In order to determine the threshold levels of NC required for
gRNA packaging, a MLV zinc knuckle mutant was ﬁrst constructed
and characterized. A single mutation of Trp 35 within the zinc
knuckle of NC was selected based on (i) previous studies demon-
strating that mutations of this residue do not affect MLV assembly
but lead to signiﬁcant reductions in gRNA packaging (Gorelick
et al., 1988; Me´ric and Goff, 1989), and (ii) in vitro structural and
biophysical studies showing that this residue contributes to the
high-afﬁnity gRNA binding (D’Souza and Summers, 2004).
To examine the impact of the Trp 35 NC mutation on virus
production, 293T-derived ET cells (Pfeiffer et al., 1999) were
transfected with WT and W35G mutant proviral plasmids
(pGPP(WT) and pGPP(W35G), Fig. 2A), and virus production was
quantiﬁed by a reverse transcriptase (RT) assay (Fig. 2B). Media
harvested from cells transfected with the W35G mutant proviral
plasmid exhibited an approximate two-fold reduction in RT
activity per volume compared to those transfected with the WT
proviral plasmid (Fig. 2B).
To determine the cause of this decrease in RT release into the
medium, viral and cell-associated proteins of the WT and W35G
mutant were compared by western blot analysis (Fig. 2C and D).
Viral protein lysates revealed an approximate two-fold reductionFig. 3. W35G NC mutant gRNA. (A) RPA of viral RNA harvested from cells transfected w
on the right. Lane markers include: undigested probe [P] (pAO993-11), RNA size marke
content by RT activity. (B) Quantiﬁcation of gRNA packaging shown in (A) by phosphor
Quantiﬁcation represents the mean of four independent experiments and the error bars
RNA harvested from cells transfected with pGPP(WT) and pGPP(W35G). RNAs were subj
the gRNA dimer and denatured gRNA monomer are indicated. The sample lanes contain
like intensities to compensate for reduced gRNA packaging levels.in total Gag (Pr65Gag and p30 CA) released from cells for the
W35G mutant relative to WT (Fig. 2C, lanes 1 and 2). Conversely,
western blot analysis of cellular lysates revealed an approximate
two-fold increase in total Gag retained in cells for the W35G
mutant (Fig. 2D, lanes 1 and 2). This result suggests that introdu-
cing the W35G mutation into NC resulted in a modest (approxi-
mately two-fold) reduction in virus release from ET cells.
In contrast, although minor differences in Pr65Gag amounts
were revealed by western blot analysis, no difference in the
pattern of proteolytic processing was observed between WT and
the W35G mutant (Fig. 2C and D). These results are consistent
with previous studies (Gorelick et al., 1988; Me´ric and Goff,
1989), and suggest that the W35G mutation does not alter Gag
processing and has little effect on virus release in ET cells.
Virus production of the W35G mutant was also examined in
NIH 3T3 cells. 3T3 cells were stably transduced with pGPP(WT)
and pGPP(W35G) and viral and cell-associated protein lysates
were compared by western blot analysis (Fig. 2E and F). In
contrast to virus production observed in ET cells, the W35G
mutant exhibited a severe release defect relative to WT in 3T3
cells (Fig. 2E), despite similar protein expression levels in cells
(Fig. 2F). These results suggest that there are cell type speciﬁc
differences in the ability of W35G NC to support virus assembly.
Transfected ET cells were used for virus production in subsequent
experiments below.
W35G NC mutant virus gRNA packaging and dimerization
To determine the gRNA packaging phenotype of the W35G
mutant, the amount of gRNA packaged in virions produced from
ET cells transfected with WT and W35G proviral plasmids wasith pGPP(WT) and pGPP(W35G). Mobilities of gRNA and 7SL products are indicated
rs [M], and digested probe-alone control [C]. Gel loading was normalized for virion
imager analysis is presented as ratios of gRNA/7SL, with the WT level set to 100%.
indicate the standard error of the means. (C) Non-denaturing northern blot of viral
ected to the indicated temperature for 10 min prior to electophoresis. Migrations of
ing RNAs isolated from the W35G virus (lanes 8 to 13) were image-adjusted to WT-
Fig. 4. WT and W35G NC phenotypically mixed virion production.
(A) Quantiﬁcation of viral release into the culture media and (B) Western blot of
lysates of virus harvested from media from cells transfected with the indicated
ratios (W35G/WT) of pGPP(W35G) and pGPP(WT). Values for phenotypically
mixed virions in (A) are normalized to WT levels, which are set to 100%. Data
represent the means of at least 5 independent experiments. Error bars indicate the
standard error of the means.
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were hybridized to a chimeric riboprobe containing sequences
complementary to both MLV gRNA and 7SL, which is a host RNA
packaged by MLV at levels proportional to virion proteins
(Onafuwa-Nuga et al., 2005) (Fig. 3A). RNA from the same amount
of virions, as quantiﬁed by RT activity, was loaded in each lane,
with 7SL serving as an RNA internal control. Quantiﬁcation of
gRNA/7SL ratios revealed that gRNA packaging levels in the W35G
mutant virions were approximately 5% of WT levels (Fig. 3B), in
agreement with previous reports (Gorelick et al., 1988; Me´ric and
Goff, 1989).
Next, the impact of the W35G mutation on gRNA dimerization
was examined by non-denaturing northern blotting (Fig. 3C). The
results showed that nondenatured W35G mutant and WT virus
gRNAs had indistinguishable gel mobilities (Fig. 3C, lanes 1 and
8), i.e., they migrated at the dimer position. Furthermore, the
thermostability of the dimer linkage for W35G and WT gRNAs did
not differ signiﬁcantly (Fig. 3C, lanes 2 to 7 and 9 to 13).
Additionally, the amount of RNA fragmentation, a characteristic
typical of retroviral gRNAs (Cofﬁn, 1979; Johnson and Telesnitsky,
2010), was no greater for the W35G mutant than for the WT
(Fig. 3C).
WT and W35G NC incorporation into phenotypically mixed virions
The above studies demonstrated that the W35G mutation
inhibits gRNA packaging without signiﬁcantly affecting virus
release from transfected human cells, gRNA dimerization, gRNA
integrity, or proteolytic processing of Gag. The mutation was
therefore considered suitable for gRNA packaging studies using
phenotypically mixed virions, which were prepared by co-expres-
sing WT and W35G proviral expression plasmids at various input
ratios.
As observed above, virion release for the W35G mutant alone
was approximately two-fold lower then for WT (Fig. 4A, lanes
1 and 2). With virions produced from co-transfection of various
input ratios of WT and W35G mutant plasmids, release recovered
to near WT levels as the amount of input WT NC plasmid
increased from 1% to 50% (Fig. 4A, lanes 3 to 10). Western blot
analysis conﬁrmed both the modest release defect of the W35G
mutant alone (Fig. 4B, lanes 1 and 2) and the recovery to near WT
levels of virus release as the amount of input WT NC plasmid
increased from 1% to 50% (Fig. 4B, lanes 3 to 10).
Although these experiments examined virion production when
W35G and wild type Gag were co-expressed, they did not directly
address whether or not protein mixtures co-assembled to form
individual virions. To determine if there was a bias in the
incorporation of WT or W35G mutant NC into the phenotypically
mixed virions, the assumption that virions contained ratios of WT
and W35G NC that matched the stoichiometry of the input proviral
expression plasmids was then tested. For this assay, packaging-
defective MLV plasmids containing either WT or W35G NCs (called
pDCMLV and pDCMLV(W35G), respectively) were transfected
into ET cells in combination with a packaging-defective MLV
plasmid containing a protease-inactivating aspartic acid-to-serine
mutation at amino acid position 32 (pDCMLV(PR)) (Fig. 5A). This
approach for testing co-assembly of co-expressed Gag proteins was
designed to ensure that any proteolytic processing in newly
formed virions was due to the incorporation of catalytically active
protease associated with either a WT or W35G mutant NC-
containing polyprotein.
Western blotting conﬁrmed that virus harvested from ET cells
transfected with pDCMLV(PR) was defective in the proteolytic
processing of Gag (Fig. 5B, lane 1). Phenotypically mixed virions
harvested from cells co-transfected with pDCMLV(PR) and
increasing concentrations of the plasmids pDCMLV orpDCMLV(W35G) displayed increased Gag processing as the
amount of protease competent MLV increased (Fig. 5B, lanes
2 to 4 and 5 to 7). Even at the highest level of WT PR examined
here (30%; Fig. 5B lanes 4 and 7)), Gag processing was signiﬁ-
cantly lower than that observed for WT (Fig. 2C) presumably
because the PR point mutant used here associates at random with
WT PR monomers in mixed virions to generate inactive PRþ: PR
heterodimers. However, overall, the Gag processing proﬁle at
each concentration of protease-competent MLV was the same,
regardless of whether the PRþ plasmid contained WT or W35G
mutant NC (Fig. 5B, lanes 2 to 4 and 5 to 7). These results suggest
that there was no bias in virion incorporation of either WT or
W35G NC and support the assumption that the ratios of WT and
W35G NC in individual phenotypically mixed virions matched the
input proviral expression plasmid ratios.
gRNA packaging in phenotypically mixed virions
Having produced phenotypically mixed virions, and performed
control experiments to examine biases in the co-assembly of WT
and W35G mutant NCs, the gRNA packaging efﬁciency of these
virions was determined by RPA. RNA harvested from phenotypi-
cally mixed virons was normalized to RT activity and probed with
a chimeric riboprobe that recognized both gRNA and 7SL. As
observed above, quantiﬁcation of gRNA/7SL ratios showed that
gRNA packaging levels for the W35G mutant were approximately
5% of WT levels (Fig. 6A and B, lanes 1 and 2). With phenotypically
mixed virions, gRNA packaging recovered to near WT levels as the
Fig. 5. WT and W35G NC incorporation into phenotypically mixed virions. (A) Diagram of DCMLV vectors. pNCA is the parental infectious MLV proviral clone from
which the following vectors were derived. pDCMLV contains a ‘‘classicC’’ deletion (Mann et al., 1983). pDCMLV(PR) and pDCMLV(W35G) contain ‘‘classicC’’ deletions
and also contain single amino acid substitutions in protease (D32S) and NC (W35G) respectively. (B) Western blot of virus lysates of phenotypically mixed virions
produced from cells transfected with pDCMLV(PR) and increasing concentrations of PRþMLV (pDCMLV or pDCMLV(W35G)). The following three PR/PRþ ratios were
utilized: 1/0.01, 1/0.10, and 1/0.30). The plasmid pMCPuro was included in each transfection to serve as gRNA. Full length Pr65Gag and processed p30 CA are indicated on
the right.
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present (Fig. 6A and B, lanes 3 to 10). When the amount of WT NC
was approximately 5–10% of the total, gRNA packaging recovered
to within two-fold of WT levels (Fig. 6A and B, lanes 5 to 7).Phenotypically mixed virus single-cycle infectivity
To determine whether packaging efﬁciency was the only
replication defect of W35G NC containing virions, replication of
phenotypically mixed virions was analyzed using a single-cycle
infectivity assay. Virions produced from ET cells co-transfected
with various ratios of pGPP(WT) and pGPP(W35G) mutant pro-
viral plasmids were used to infect fresh target cells. Because pGPP
derivatives contain a puromycin N-acetyltransferase (puroR) gene
in place of the env open reading frame, provirus titer represented
as puromycin-resistant colony forming units per milliliter (CFU/
mL) could be determined (Fig. 7). The titer of the W35G mutant,
when normalized for virion abundance, was decreased approxi-
mately 1000-fold relative to WT (Fig. 7A, lanes 1 and 2). For the
phenotypically mixed virions, titer recovered as the amount of
WT NC increased from 1% to 50% of the total NC and plateaued at
approximately half of WT levels (Fig. 7A, lanes 3 to 10).
To determine what portion of the decrease in viral titer was
due to gRNA packaging defects, the results were also normalized
to input gRNA levels as measured by RPA (Fig. 6). In this case, the
titer for virions containing 100% W35G mutant was approxi-
mately 100-fold lower than WT (Fig. 7B, lanes 1 and 2). Again,
titer recovered to only half of WT levels as the amount of WT NC
increased from 1% to 50% of the total NC (Fig. 7B, lanes 3 to 10).Analysis of reverse transcription error rates of phenotypically
mixed virus
The above results suggested that in addition to inhibiting
gRNA packaging, the W35G mutation negatively impacted other
NC functions early in the infection process. To test if errors in
reverse transcription contributed to the decrease in proviral titer
of the W35G mutant, a lacZ inactivation assay was performed
(Pfeiffer et al., 1999; 2000; Brincat et al., 2002). In these experi-
ments, virions comprised of phenotypic mixtures of WT and
W35G Gag, and which packaged a dual marker vector expressing
both lacZ and puroR, were generated as described in Materials and
Methods. These were used to infect fresh target cells, and
provirus-containing puromycin resistant colonies were stained
with X-Gal and counted (Fig. 8). Consistent with the results
described above, colony forming unit titer decreased as the
amount of WT NC decreased to 1% of the total NC (Fig. 8B, lanes
1 to 5). Additionally, the titer of the W35G mutant alone was
decreased approximately 1000-fold relative to WT alone (Fig. 8B,
lanes 1 and 7).
Consistent with previous studies (Pfeiffer et al., 2000, Brincat
et al., 2002), the lacZ inactivation rate, represented as the percent
of white colonies relative to the total number of colonies (% white
colonies), for WT virus was approximately 10% (Fig. 8C, lane 1),
and lacZ inactivation from control phenotypically mixed virions
containing 95% RNAse H (RH) mutant and 5% WT RH increased
approximately two-fold relative to WT only (Fig. 8C, lane 1 and 8).
In the experimental samples, lacZ inactivation rates remained
relatively unchanged for virions containing as little as 10% WT NC
(Fig. 8C). However, with phenotypically mixed virions containing
lower ratios of WT to W35G NC, the lacZ inactivation rates
Fig. 6. gRNA packaging of WT and W35G NC phenotypically mixed virions.
(A) RPA of viral RNA harvested from cells transfected with the indicated ratios
(W35G/WT) of pGPP(W35G) and pGPP(WT). gRNA and 7SL bands are indicated on
the right. Lane markers include: undigested probe [P] (pEG467-10), RNA size
markers [M], and digested probe-alone control [C]. Gel loading was normalized for
virion content by RT activity. (B) Quantiﬁcation of gRNA packaging shown in
(A) by phosphorimager analysis is presented as ratios of gRNA/7SL, with the WT
level set to 100%. Quantiﬁcation represents the mean of at least three independent
experiments and the error bars indicate the standard error of the means.
Fig. 7. Infectivity of WT and W35G NC pheotypically mixed virions. Titer of
virus produced from cells transfected with the indicated ratios (W35G/WT) of
pGPP(W35G) and pGPP(WT). Data was initially collected as puromycin-resistant
colony forming units per mL (CFU/mL) and is presented in (A) normalized to virion
RT activity (Fig. 4) and (B) to virion gRNA packaging levels (Fig. 6). Quantiﬁcation
represents the mean of at least three independent infections (of duplicate plates)
with virons produced from at least three independent transfections. Error bars
indicate the standard error of the means.
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of W35G mutant virus alone was 100%, as no blue colonies (out of
58 total colonies across ﬁve independent infections) were
observed (Fig. 8C, lane 6). Taken together, these results suggest
that in addition to decreases in gRNA packaging, errors in reverse
transcription contributed to, but do not fully account for,
decreases in provirus generation by W35G virus.Discussion
The current model of gRNA packaging for MLV, based on
in vitro binding studies, predicts that only a small number of
functional Gag molecules (possibly only 12, or r1% of all Gag
molecules) are required to engage in high-afﬁnity interactions
with gRNA to initiate retroviral assembly. This packaging model is
consistent with ﬂuorescence microscopy studies in cells, which
indicate that the HIV dimeric RNA genome is trafﬁcked to plasma
membrane assembly sites by a small number (a dozen or fewer)of HIV-1 Gag proteins (Jouvenet et al., 2009). The goal of the
present study was to test predictions derived from the in vitro
studies in a cell culture system and examine the threshold limits
of MLV Gag required to package gRNA.
Phenotypically mixed virions containing WT and packaging
deﬁcient W35G mutant NCs were found to package near WT
levels of gRNA when amounts of packaging-competent NC repre-
sented half of the total. When packaging-competent Gag was
reduced to 5–10% of the total, virions showed a modest packaging
defect (approximately two-fold). Similar results obtained for HIV-
1 (Schwartz et al., 1997) suggest that this phenotype is conserved
among retroviruses.
The results described here suggest that the threshold limits of
MLV Gag required to packaged gRNA are greater than what the
above packaging model predicts. A possible explanation for the
modest defect observed at threshold levels of functional Gag is
that the initially formed Gag NC–gRNA complex may be structu-
rally compromised, to some extent, by the presence of mutant
Gag proteins. In other words, proper gRNA packaging may require
the occupation of all high-afﬁnity NC binding sites by WT NC, and
the presence of even a small amount of mutant-NC containing
Gag might be sufﬁcient to disrupt proper packaging. Gag–Gag
interactions mediated by the wild type CA domain could help
recruit mutant Gag proteins to the packaging signal, thereby
facilitating the incorporation of mutant Gag molecules despite
the predicted reduction in NC:RNA afﬁnity.
Additional work here demonstrated a genetic separation
between gRNA packaging and other replication functions for the
Fig. 8. Reverse transcription error rates of WT and W35G NC phenotypically mixed virions. (A) Schematic overview of the lacZ inactivation assay described in the text.
(B) Titer of virus (CFU/mL) produced from cells transfected with the indicated ratios of pDCMLV, pDCMLV(W35G), or pMLVCDNAPþRH (RH). (C) lacZ inactivation
(% white colonies) of virus produced from cells transfected with the indicated ratios of the above plasmids. Quantiﬁcation in (B) and (C) represents the mean of at least four
independent infections (of duplicate plates) with virus produced from three independent transfections. Error bars indicate the standard error of the means.
S.F. Johnson et al. / Virology 430 (2012) 100–109106W35G mutant. For example, our results showed that the W35G
mutation did not impair gRNA dimer formation or gRNA integrity.
gRNA dimer formation is dependent on the ability of NC to lower
the energy barrier required to disrupt and re-form favorable base
pairing interactions within gRNA dimers (Prats et al., 1990; Girard
et al., 1996; Rein et al., 1998). In addition, the coating of gRNA
with one NC molecule every 5 to 8 nucleotides (Levin et al., 2005)
is thought to be important to protect the gRNA from nuclease
degradation both in cells (reviewed in Thomas and Gorelick,
2008) and most relevant for our results, in virions (Johnson and
Telesnitsky, 2010; Keene et al., 2010). In work describe here, the
W35G mutant retained the ability to both protect the gRNA in
virions from endoribonuclease digestion and promote the forma-
tion of gRNA dimers.
An additional phenotype of the W35G mutant described here
was a modest but reproducible release defect in human 293T-
derived ET cells. This corresponded to an increase in cell-asso-
ciated viral protein, suggesting that Gag was retained in the cells.
This phenotype has been observed in human cells with other NC
mutants that have been shown to impair MLV assembly (Muriaux
et al., 2004). Defects in virus release may be due to disruptions in
NC-gRNA interactions in higher order Gag oligomers that are
responsible for forming the structure of newly forming virions
(reviewed in Rein et al., 2011). Here, virus release from ET cells
recovered when the amount of WT Gag in phenotypically mixed
virions approached half of the total Gag, suggesting that the NC-
gRNA interactions required to form higher order Gag oligomers do
not require a full complement of packaging competent Gag.
Experiments described here were performed in human cells
based on our observation that W35G virus release was severely
attenuated in murine cells. This result correlates with previous
studies where MLV NC Trp 35 mutants were shown to quicklyrevert to WT upon passaging in murine cells (Gorelick et al., 1988;
Me´ric and Goff, 1989).
Our results demonstrated that the W35G mutant was approxi-
mately 100-fold less infectious than WT in a single cycle infectiv-
ity assay, when normalized for packaged gRNA levels.
Interestingly, in phenotypically mixed virions, infectivity did not
recover to WT-like levels at the same W35G:WT NC ratio as virus
release or gRNA packaging, suggesting that a full complement of
WT NC may be required for productive early infection events.
NC is known to have many functions in the early steps of
retroviral replication which are dependent on its nucleic acid
chaperone activity (reviewed in Levin et al., 2005; Thomas and
Gorelick, 2008; Levin et al., 2010; Darlix et al., 2011). For example,
aberrant reverse transcription products result when NC’s chaper-
one functions are impaired by mutating zinc-coordinating resi-
dues (Gorelick et al., 1996; 1999), and Trp 35 mutant MLV NC has
been shown to decrease reverse transcription through regions of
RNA secondary structure (Zhang et al., 2002). Consistent with the
notion that disrupting NC’s chaperones function results in aber-
rant reverse transcription products, we observed defects in
reverse transcription for the W35G mutant as measured by a
genetic marker inactivation assay for phenotypiclally mixed
virions containing Z95% W35G. Although not tested explicitly,
the observation of large decreases in titer at low W35G concen-
trations suggests that additional defects, such as in reverse
transcription initiation, may have contributed to the defects in
W35G virion infectivity. Published work showing that primer tRNA
placement and annealing are dependent on retroviral NC’s chaper-
one function are consistent with this notion (Levin et al., 2010).
In summary, the work presented here showed that MLV zinc
knuckle mutant W35G and WT NC Gag molecules readily
co-assembled, and that the resulting phenotypically mixed virions
S.F. Johnson et al. / Virology 430 (2012) 100–109 107encapsidated roughly half as much gRNA as wild type particles
when a 5–10% threshold of WT NC was reached. These studies also
demonstrated that authentic dimerization of MLV gRNAs and the
maintenance of gRNA integrity were independent of the chaperone
functions provided by the MLV NC zinc knuckle. Nonetheless,
replication defects for phenotypically mixed virions were greater
than those predicted by gRNA packaging levels, further under-
scoring the myriad roles of NC in retroviral replication.Materials and methods
Cells and transfectons.
ET cells, which are 293T cells that constitutively expresses
murine ecotropic envelope, and ET-pLacPuro cells, which are ET
cells that constitutively express an MLV vector containing both a
LTR promoter driven lacZ gene and a simian virus 40 (SV40)
promoter driven pruomycin N-acetltransferase (puroR) gene in
place of the viral genes (Pfeiffer et al., 1999), were maintained in
Dulbecco’s modiﬁed Eagles’s medium (DMEM; Invitrogen) sup-
plemented with 10% fetal bovine serum (Gemini), 100 U/mL
penicillin, and 100 mg/mL streptomycin (Invitrogen). D17/pJET
cells, a canine osteosarcoma cell line that constitutively expresses
murine ecotropic receptor (O’Reilly and Roth, 2000), and NIH 3T3
cells were maintained in DMEM supplemented with 10% bovine
serum (Invitrogen), 100 U/mL penicillin, and 100 mg/mL strepto-
mycin (Invitrogen). Both ET and D17/pJET cells were grown at
37 1C with 5% CO2 in a humidiﬁed incubator. Transfections were
carried out using polyethlenimine (PEI) as described previously
(Keene et al., 2010).Plasmids
The MLV-based gag-pol-puro plasmid, pGPP(WT) (aka
pSRK876-15), contains an intact provirus modiﬁed by the repla-
cement of the env open reading frame with a puroR driven by a
SV40 promoter (Fig. 2A) (Pfeiffer et al., 1999). The W35G NC
mutation in pGPP(W35G) (aka pEG479-1) was generated by
overlap extension PCR, sequenced, and used to replace the
corresponding portion of pGPP(WT) (Fig. 2A).
The ‘‘classic C’’ deletion (D215–568) (Mann et al., 1983) in
pDCMLV (aka pAO147-2) was generated by overlap extension
PCR, sequenced, and used to replace the corresponding portion of
pNCA (Colicelli and Goff, 1988) (Fig. 5A). A restriction fragment
encompassing the W35Gmutation in NC of pGPP(W35G) replaced
the corresponding portion of pDCMLV to generate
pDCMLV(W35G) (aka pSFJ93-1) (Fig. 5A). For pDCMLV(PR)
(aka pSFJ229-1), site directed mutagenesis was performed using
the QuikChange II Site-Directed Mutagenesis Kit (Stratagene) to
introduce an aspartic acid-to-serine mutation at amino acid
position 32 of MLV protease (PR) in pDCMLV, which sequencing
conﬁrmed (Fig. 5A). Construction of the MLV packaging vector
pMCPuro (aka pAM86-5) and the RNAse H mutant (D524N)
plasmid pMLVC–DNAPþRH (aka pTW76–3) were described
previously (Kulpa et al., 1997; Brincat et al., 2002).
The riboprobe templates were derivatives of pBSII SK(þ)
(Stratagene) that contained PCR fragments inserted into the
EcoRV site. The PCR insert in pAO993-11 includes complementar-
ity to portions of both MLV 50-UTR (nucleotides(nt) 55–255) and
100 nt of 7SL RNA (Onafuwa-Nuga et al., 2005). The insert in
pEG467-10, which was generated by PCR from pAO993-11, also
included complementarity to portions of both MLV 50-UTR (nt 55–
214) and 100 nt of 7SL RNA (Garcia et al., 2009).Virus isolation
Virus was isolated from tissue culture supernatants harvested
at 48 h post transfection by centrifugation (Keene et al., 2010). For
western blotting, the viral pellets were resuspended in RIPA lysis
buffer (1% NP40, 0.1% sodium dodecyl sulfate, 0.5% sodium
deoxycholate, 150 mM Nacl, 50 mM Tris [pH7.5]) supplemented
with 1X protease inhibitor cocktail (PIC) tablet (Roche) and 1 mM
phenylmethylsulfonyl ﬂuoride (PMSF). Viral protein lysates were
stored at 20 1C. For RNAse protections assays, viral pellets were
resuspended in TRIzol
s
reagent (Invitrogen) and stored at 80 1C.
For non-denaturing northern blots, RNA was isolated from viral
pellets using proteinase K-based extraction (Flynn et al., 2004).
Virus was quantiﬁed using an exogenous reverse transcriptase
(RT) assay (Garcia et al., 2009) based on a previously described
protocol (Telesnitsky et al., 1995).
Western blotting
Total cell protein was harvested in RIPA lysis buffer supple-
mented with 1X PIC tablet (Roche) and 1 mM PMSF. Cells were
ﬁrst lysed on ice for 30 min in RIPA buffer and then cleared by
centrifugation at 13,000 rpm for 20 min at 4 1C. Virus lysates were
prepared as described above.
Cell and virus lysates were resolved by SDS-PAGE and trans-
ferred to polyvinylidene ﬂuoride (PVDF; Bio-Rad) membranes
overnight using a Mini-PROTEANs 3 Cell transfer apparatus
(Bio-Rad). Membranes were blocked in 1% nonfat dried milk in
TBS (50 mM Tris [pH7.5], 150 mM NaCl) for 1 h at room tempera-
ture. After blocking, membranes were incubated with primary
antibodies diluted in 1% nonfat dried milk in TBS containing 0.1%
Tween-20 (TBS-T), for 1 h at room temperature. The rat mAb
against MLV p30 CA was derived from hybridoma supernatants
(from Bruce Chesebro: ATCC clone R187) and diluted 1:600. The
beta-actin mAb (Ambion: AM4302) was diluted 1:5000.
Secondary antibodies were diluted in 1% nonfat dried milk in
TBS-T and incubated for 1 h at room temperature. The following
dye-conjugated secondary antibodies were utilized at a 1:7500
dilution: goat anti-rat IRDyes 800CW and goat anti-mouse
IRDyes 680 (Li-Cor Biosciences). After incubation in both primary
and secondary antibodies, the membranes were washed 3 times
with TBS-T. A ﬁnal wash in TBS was performed before proteins
were detected and quantiﬁed using the Li-Cor Odyssey system
(Li-Cor Biosciences).
RNAse protection assay (RPA)
To produce riboprobes, pAO993-11 and pEG467-10 (see
above) were linearized with HindIII and in vitro transcribed using
T3 RNA polymerase (Promega) and [a-32P]-rCTP (Perkin-Elmer).
pAO993-11 protects 200 nt of MLV gRNA and 100 nt of 7SL RNA
while pEG467-10 protects 163 nt of MLV gRNA and 100 nt of 7SL
RNA, respectively. Hybridization of riboprobes with sample RNA,
RNAse digestion, and resolution was carried out as described
previously (Miyazaki et al., 2010a).
Non-denaturing northern blot
Non-denaturing northern blot analysis of viral RNAs isolated
by the proteinase-K-based extraction method (see above) was
carried out as described previously (Miyazaki et al., 2010a).
Infections
D17/pJET cells were infected in 35 mm dishes for 4 h in
the presence of hexadimethrine bromide (Polybrene; Sigma).
S.F. Johnson et al. / Virology 430 (2012) 100–109108Virus-containing media was then removed and cells were trans-
ferred to 10 cm dishes. 48 h post infection, media containing 2 mg/mL
puromycin was added and after 12 day of selection, colonies were
stained with crystal violet for counting. Infectious units are
represented as colony forming units per milliliter (CFU/mL).
lacZ inactivation assay
Virions produced from ET-pLacPuro cells co-transfected with
various ratios of pDCMLV and pDCMLV(W35G) or pMLVCDNAPþ
RH mutant proviral plasmids were used to infect D17/pJET cells as
described above. After selection, colonies were stained with 5-bromo-
4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal) and counted.Acknowledgments
We thank Kathy Spindler and Akira Ono for constructive
comments on the manuscript.
This work was supported by NIH grant RO1GM042561 to MFS
and AT, with early phase support from R01CA069300 to AT.
References
Berkowitz, R.D., Ohagen, A., Ho¨glund, S., Goff, S.P., 1995. Retroviral nucleocapsid
domains mediate the speciﬁc recognition of genomic viral RNAs by chimeric
Gag polyproteins during RNA packaging in vivo. J. Virol. 69, 6445–6456.
Brincat, J.L., Pfeiffer, J.K., Telesnitsky, A., 2002. RNase H activity is required for
high-frequency repeat deletion during Moloney murine leukemia virus repli-
cation. J. Virol. 76, 88–95.
Carlson, L.-A., Briggs, J.A.G., Glass, B., Riches, J.D., Simon, M.N., Johnson, M.C.,
Mu¨ller, B., Gru¨newald, K., Kra¨usslich, H.G., 2008. Three-dimensional analysis of
budding sites and released virus suggests a revised model for HIV-1 morpho-
genesis. Cell Host Microbe 4, 592–599.
Cofﬁn, J.M., 1979. Structure, replication, and recombination of retrovirus genomes:
some unifying hypotheses. J. Gen. Virol. 42, 1–26.
Colicelli, J., Goff, S.P., 1988. Sequence and spacing requirements of a retrovirus
integration site. J. Mol. Biol. 199, 47–59.
D’Souza, V., Summers, M.F., 2004. Structural basis for packaging the dimeric
genome of Moloney murine leukaemia virus. Nature 431, 586–590.
D’Souza, V., Summers, M.F., 2005. How retroviruses select their genomes. Nat. Rev.
Microbiol. 3, 643–655.
Darlix, J.L., Godet, J., Ivanyi-Nagy, R., Fosse´, P., Mauffret, O., Me´ly, Y., 2011. Flexible
nature and speciﬁc functions of the HIV-1 nucleocapsid protein. J. Mol. Biol.
410, 565–581.
Dey, A., York, D., Smalls-Mantey, A., Summers, M.F., 2005. Composition and
sequence-dependent binding of RNA to the nucleocapsid protein of Moloney
murine leukemia virus. Biochemistry 44, 3735–3744.
Fisher, J., Goff, S.P., 1998. Mutational analysis of stem-loops in the RNA packaging
signal of the Moloney murine leukemia virus. Virology 244, 133–145.
Flynn, J.A., An, W., King, S.R., Telesnitsky, A., 2004. Nonrandom dimerization of
murine leukemia virus genomic RNAs. J. Virol. 78, 12129–12139.
Ganser-Pornillos, B.K., Yeager, M., Sundquist, W.I., 2008. The structural biology of
HIV assembly. Curr. Opin. Struct. Biol. 18, 203–217.
Garcia, E.L., Onafuwa-Nuga, A.A., Sim, S., King, S.R., Wolin, S.L., Telesnitsky, A.,
2009. Packaging of host mY RNAs by murine leukemia virus may occur early in
Y RNA biogenesis. J. Virol. 83, 12526–12534.
Gherghe, C., Lombo, T., Leonard, C.W., Datta, S.A.K., Bess, J.W., Gorelick, R.J., Rein,
A.R., Weeks, K.M., 2010. Deﬁnition of a high-afﬁnity Gag recognition structure
mediating packaging of a retroviral RNA genome. Proc. Nat. Acad. Sci. USA 107,
19248–19253.
Girard, P.M., de Rocquigny, H., Roques, B.P., Paoletti, J., 1996. A Model of PSI
dimerization: destabilization of the C278G303 Stem–Loop by the nucleo-
capsid protein (NCp10) of MoMuLV. Biochemistry 35, 8705–8714.
Gonsky, J., Bacharach, E., Goff, S.P., 2001. Identiﬁcation of residues of the Moloney
murine leukemia virus nucleocapsid critical for viral DNA synthesis in vivo.
J. Virol. 75, 2616–2626.
Gorelick, R.J., Chabot, D.J., Ott, D.E., Gagliardi, T.D., Rein, A.R., Henderson, L.E.,
Arthur, L.O., 1996. Genetic analysis of the zinc ﬁnger in the Moloney murine
leukemia virus nucleocapsid domain: replacement of zinc-coordinating resi-
dues with other zinc-coordinating residues yields noninfectious particles
containing genomic RNA. J. Virol. 70, 2593–2597.
Gorelick, R.J., Fu, W., Gagliardi, T.D., Bosche, W.J., Rein, A.R., Henderson, L.E.,
Arthur, L.O., 1999. Characterization of the block in replication of nucleocapsid
protein zinc ﬁnger mutants from moloney murine leukemia virus. J. Virol. 73,
8185–8195.
Gorelick, R.J., Henderson, L.E., Hanser, J.P., Rein, A.R., 1988. Point mutants of
Moloney murine leukemia virus that fail to package viral RNA: evidence forspeciﬁc RNA recognition by a ‘‘zinc ﬁnger-like’’ protein sequence. Proc. Nat.
Acad. Sci. USA 85, 8420–8424.
Henderson, L.E., Copeland, T.D., Sowder, R.C., Smythers, G.W., Oroszlan, S., 1981.
Primary structure of the low molecular weight nucleic acid-binding proteins of
murine leukemia viruses. J. Biol. Chem. 256, 8400–8406.
Johnson, S.F., Telesnitsky, A., 2010. Retroviral RNA dimerization and packaging: the
what, how, when, where, and why. PLoS Pathog. 6 (10), e1001007, http://dx.do
i.org/10.1371/journal.ppat.1001007.
Jouvenet, N., Simon, S., Bieniasz, P.D., 2009. Imaging the interaction of HIV-1
genomes and Gag during assembly of individual viral particles. Proc. Nat. Acad.
Sci. USA 106, 19114–19119.
Keene, S.E., King, S.R., Telesnitsky, A., 2010. 7SL RNA is retained in HIV-1 minimal
virus-like particles as an S-domain fragment. J. Virol. 84, 9070–9077.
Kulpa, D., Topping, R.S., Telesnitsky, A., 1997. Determination of the site of ﬁrst
strand transfer during Moloney murine leukemia virus reverse transcription
and identiﬁcation of strand transfer-associated reverse transcriptase errors.
EMBO J. 16, 856–865.
Levin, J.G., Guo, J., Rouzina, I., Musier-Forsyth, K., 2005. Nucleic acid
chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse
transcription and molecular mechanism. Prog. Nucleic Acid Res. Mol. Biol.
80, 217–286.
Levin, J.G., Mitra, M., Mascarenhas, A.P., Musier-Forsyth, K., 2010. Role of HIV-1
nucleocapsid protein in HIV-1 reverse transcription. RNA Biol. 7, 754–774.
Lu, K., Heng, X., Summers, M.F., 2011. Structural determinants and mechanism of
HIV-1 genome packaging. J. Mol. Biol. 410, 609–633.
Mann, R., Mulligan, R.C., Baltimore, D., 1983. Construction of a retrovirus packa-
ging mutant and its use to produce helper-free defective retrovirus. Cell 33,
153–159.
Me´ric, C., Goff, S.P., 1989. Characterization of Moloney murine leukemia virus
mutants with single-amino-acid substitutions in the Cys-His box of the
nucleocapsid protein. J. Virol. 63, 1558–1568.
Miyazaki, Y., Garcia, E.L., King, S.R., Iyalla, K., Loeliger, K., Starck, P., Syed, S.,
Telesnitsky, A., Summers, M.F., 2010a. An RNA structural switch regulates
diploid genome packaging by Moloney murine leukemia virus. J. Mol. Biol.
396, 141–152.
Miyazaki, Y., Irobalieva, R.N., Tolbert, B.S., Smalls-Mantey, A., Iyalla, K., Loeliger, K.,
D’Souza, V., Khant, H., Schmid, M.F., Garcia, E.L., Telesnitsky, A., Chiu, W.,
Summers, M.F., 2010b. Structure of a conserved retroviral RNA packaging
element by NMR spectroscopy and cryo-electron tomography. J. Mol. Biol. 404,
751–772.
Morellet, N., Jullian, N., de Rocquigny, H., Maigret, B., Darlix, J.-L., Roques, B.P.,
1992. Determination of the structure of the nucleocapsid protein NCp7 from
the human immunodeﬁciency virus type 1 by 1H NMR. EMBO J. 11,
3059–3065.
Muriaux, D., Costes, S., Nagashima, K., Mirro, J., Cho, E., Lockett, S., Rein, A.R., 2004.
Role of murine leukemia virus nucleocapsid protein in virus assembly. J. Virol.
78, 12378–12385.
Muriaux, D., Mirro, J., Harvin, D.P., Rein, A.R., 2001. RNA is a structural element in
retrovirus particles. Proc. Nat. Acad. Sci. USA 98, 5246–5251.
O’Reilly, L., Roth, M.J., 2000. Second-site changes affect viability of amphotropic/
ecotropic chimeric enveloped murine leukemia viruses. J. Virol. 74, 899–913.
Onafuwa-Nuga, A.A., King, S.R., Telesnitsky, A., 2005. Nonrandom packaging of
host RNAs in moloney murine leukemia virus. J. Virol. 79, 13528–13537.
Pfeiffer, J.K., Georgiadis, M.M., Telesnitsky, A., 2000. Structure-based moloney
murine leukemia virus reverse transcriptase mutants with altered intracel-
lular direct-repeat deletion frequencies. J. Virol. 74, 9629–9636.
Pfeiffer, J.K., Topping, R.S., Shin, N.H., Telesnitsky, A., 1999. Altering the intracel-
lular environment increases the frequency of tandem repeat deletion during
Moloney murine leukemia virus reverse transcription. J. Virol. 73, 8441–8447.
Prats, A.C., Roy, C., Wang, P., Erard, M., 1990. cis elements and trans-acting factors
involved in dimer formation of murine leukemia virus RNA. J. Virol. 64,
774–783.
Rein, A.R., Datta, S.A.K., Jones, C.P., Musier-Forsyth, K., 2011. Diverse interactions of
retroviral Gag proteins with RNAs. Trends Biochem. Sci. 36, 373–380.
Rein, A.R., Harvin, D.P., Mirro, J., Ernst, S.M., Gorelick, R.J., 1994. Evidence that a
central domain of nucleocapsid protein is required for RNA packaging in
murine leukemia virus. J. Virol. 68, 6124–6129.
Rein, A.R., Henderson, L.E., Levin, J.G., 1998. Nucleic-acid-chaperone activity of
retroviral nucleocapsid proteins: signiﬁcance for viral replication. Trends
Biochem. Sci. 23, 297–301.
Schwartz, M.D., Fiore, D., Panganiban, A.T., 1997. Distinct functions and require-
ments for the Cys-His boxes of the human immunodeﬁciency virus type
1 nucleocapsid protein during RNA encapsidation and replication. J. Virol. 71,
9295–9305.
South, T.L., Blake, P.R., Hare, D.R., Summers, M.F., 1991. C-Terminal retroviral-type
zinc ﬁnger domain from the HIV-1 nucleocapsid protein is structurally similar
to the N-terminal zinc ﬁnger domain. Biochemistry 30, 6342–6349.
South, T.L., Summers, M.F., 1993. Zinc- and sequence-dependent binding to
nucleic acids by the N-terminal zinc ﬁnger of the HIV-1 nucleocapsid protein:
NMR structure of the complex with the Psi-site analog, dACGCC. Protein Sci. 2,
3–19.
Summers, M.F., Henderson, L.E., Chance, M.R., Bess, J.W., South, T.L., Blake, P.R.,
Sagi, I., Perez-Alvarado, G., Sowder, R.C., Hare, D.R., 1992. Nucleocapsid zinc
ﬁngers detected in retroviruses: EXAFS studies of intact viruses and the
solution-state structure of the nucleocapsid protein from HIV-1. Protein Sci.
1, 563–574.
S.F. Johnson et al. / Virology 430 (2012) 100–109 109Summers, M.F., South, T., Kim, B., 1990. High-resolution structure of an HIV zinc
ﬁngerlike domain via a new NMR-based distance geometry approach—
Biochemistry (ACS Publications). Biochemistry 29, 340–346.
Telesnitsky, A., Blain, S., Goff, S.P., 1995. Assays for retroviral reverse transcriptase.
Meth. Enzymol. 262, 347–362.
Thomas, J.A., Gorelick, R.J., 2008. Nucleocapsid protein function in early infection
processes. Virus Res. 134, 39–63.Zhang, W., Hwang, C., Hu, W., Gorelick, R.J., 2002. Zinc ﬁnger domain of murine
leukemia virus nucleocapsid protein enhances the rate of viral DNA synthesis
in vivo. J. Virol. 76, 7473–7484.
Zhang, Y., Barklis, E., 1995. Nucleocapsid protein effects on the speciﬁcity of
retrovirus RNA encapsidation. J. Virol. 69, 5716–5722.
